AzTrials
AzTrials

CancerPhase 2NCT03899155

Pan Tumor Rollover Study

A Phase 2 study testing Nivolumab, Ipilimumab and Cabozantinib in people with Cancer, run by Bristol-Myers Squibb at 399 sites in 38 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Cancer
What is being tested?
Nivolumab, Ipilimumab and Cabozantinib
Could I receive a placebo?
No, everyone receives an active treatment
How many people
1,500 participants
Where
399 sitesin 38 countries
Study dates
9 Aug 2019to 25 Aug 2029
Phase
Phase 2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Signed Written Informed Consent.
  • Eligible to receive continued study treatment per the Parent Study, including treatment beyond progression per investigator assessment in the Parent Study.
  • On treatment hold in the Parent Study following long-lasting response or are eligible for treatment rechallenge as defined in the Parent Study.
  • WOCBP and male participants who are sexually active must agree to follow instructions for method(s) of contraception as described below and included in the ICF.

Who cannot join

  • Participant is not eligible for study treatment per the Parent Study eligibility criteria.
  • Participants not receiving clinical benefit as assessed by the Investigator.
  • Any clinical adverse event (AE), laboratory abnormality, or intercurrent illness which, in the opinion of the Investigator, indicates that participation in the study is not in the best interest of the participant.
  • Other protocol-defined Inclusion/Exclusion Criteria apply

Trial locations and contacts

399 sites in 38 countries. Contact the study team or a site near you to ask about taking part.

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com contact

855-907-3286

Clinical.Trials@bms.com

First line of the email MUST contain NCT # and Site #. contact

399 sites in 38 countries

United States59 sites, 7 recruiting

  • Local Institution

    Albuquerque, New Mexico, 87131

    Withdrawn

  • Local Institution - 0037

    Allentown, Pennsylvania, 18103

    Completed

  • Local Institution - 0143

    Ann Arbor, Michigan, 48109-5008

    Completed

  • Local Institution - 0233

    Aurora, Colorado, 80045

    Completed

  • Local Institution - 0092

    Baltimore, Maryland, 21287

    Completed

  • Local Institution - 0039

    Boston, Massachusetts, 02114

    Completed

  • Dana_Farber Cancer Institute (DFCI)

    Boston, Massachusetts, 02215

    David Reardon, Site 0082, 617-632-2166

    Recruiting

  • Local Institution - 0081

    Boston, Massachusetts, 02215

    Withdrawn

  • Local Institution - 0128

    Buffalo, New York, 14263

    Completed

  • Local Institution - 0228

    Charleston, South Carolina, 29414

    Completed

  • Local Institution - 0204

    Charlotte, North Carolina, 28204

    Completed

  • Local Institution

    Charlottesville, Virginia, 22908

    Withdrawn

  • Local Institution

    Chattanooga, Tennessee, 37404

    Withdrawn

  • Local Institution - 0105

    Chicago, Illinois, 60637

    Completed

  • Oncology Hematology Care

    Cincinnati, Ohio, 45242

    Patrick Ward, Site 0085, 513-751-2273

    Recruiting

  • Local Institution - 0408

    Cincinnati, Ohio, 45267

    Completed

  • Local Institution

    Cleveland, Ohio, 44106

    Withdrawn

  • The Ohio University

    Columbus, Ohio, 43210

    Asrar Alahmadi, Site 0103, 202-361-4528

    Recruiting

  • Local Institution

    Dallas, Texas, 75390

    Withdrawn

  • Local Institution - 0016

    Durham, North Carolina, 27705

    Completed

  • Local Institution - 0054

    Easton, Pennsylvania, 18045

    Completed

  • Local Institution

    Greenville, South Carolina, 29615

    Withdrawn

  • Local Institution - 0364

    Houston, Texas, 77030-4000

    Withdrawn

  • Local Institution - 0220

    Huntsville, Alabama, 35801

    Completed

  • Lancaster General Health

    Lancaster, Pennsylvania, 17601

    Samuel Kerr, Site 0400, 717-215-9561

    Recruiting

  • Local Institution - 0014

    Lebanon, New Hampshire, 03756

    Completed

  • University of Louisville-James Graham Brown Cancer Center

    Louisville, Kentucky, 40202

    Jason Chesney, Site 0059, 502-562-2280

    Recruiting

  • Innovative Clinical Research Institute

    Lynwood, California, 90262

    Withdrawn

  • Local Institution - 0065

    Madison, Wisconsin, 53792

    Completed

  • Local Institution - 0124

    Madison, Wisconsin, 53792

    Withdrawn

  • Local Institution

    Maywood, Illinois, 60153

    Withdrawn

  • NYU Langone Hematology Oncology Associates-Mineola

    Mineola, New York, 11501

    Jeffery Schneider, Site 0413, 516-578-2408

    Recruiting

  • Local Institution - 0100

    Minneapolis, Minnesota, 55407-3723

    Completed

  • Tennesse Oncology

    Nashville, Tennessee, 37203

    David Spigel, Site 0130, 615-320-5090

    Recruiting

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37232

    Withdrawn

  • Allegheny Valley Hospital

    Natrona Heights, Pennsylvania, 15065

    Withdrawn

  • Local Institution - 0095

    New Haven, Connecticut, 06520

    Withdrawn

  • Local Institution

    New York, New York, 10016

    Withdrawn

  • Local Institution - 0185

    New York, New York, 10065

    Completed

  • Local Institution - 0202

    New York, New York, 10065

    Withdrawn

  • Local Institution

    New York, New York, 10065

    Withdrawn

  • Florida Cancer Affiliates

    Ocala, Florida, 34474

    Withdrawn

  • Local Institution - 0205

    Omaha, Nebraska, 68130

    Completed

  • Local Institution

    Orlando, Florida, 32806

    Withdrawn

  • Local Institution - 0279

    Park Ridge, Illinois, 60068

    Completed

  • Local Institution

    Philadelphia, Pennsylvania, 19104

    Withdrawn

  • Local Institution - 0162

    Philadelphia, Pennsylvania, 19111

    Withdrawn

  • Local Institution - 0110

    Pittsburgh, Pennsylvania, 15213

    Completed

  • Public Hospital of King County District 1 Valley Medical Center

    Renton, Washington, 98055

    Withdrawn

  • Local Institution - 0055

    Salt Lake City, Utah, 84112-5550

    Completed

  • Local Institution

    San Francisco, California, 94115

    Withdrawn

  • Local Institution - 0099

    San Francisco, California, 94143

    Completed

  • Local Institution

    St Louis, Missouri, 63110

    Withdrawn

  • Local Institution - 0024

    Tampa, Florida, 33612

    Completed

  • University of Arizona College of Medicine

    Tucson, Arizona, 85724

    Withdrawn

  • Local Institution - 0246

    Tulsa, Oklahoma, 74146

    Withdrawn

  • Local Institution - 0088

    Washington D.C., District of Columbia, 20007-2113

    Completed

  • Local Institution - 0186

    Westwood, Kansas, 66205

    Completed

  • Local Institution - 0165

    Wichita, Kansas, 67214-3728

    Completed

Other trials in United States

Spain33 sites, 11 recruiting

  • Local Institution - 0122

    A Coruña, 15006

    Completed

  • Local Institution - 0382

    A Coruña, 15706

    Withdrawn

  • Local Institution - 0173

    Alicante, 03010

    Completed

  • Catalan Institute of Badalona Hospital Germans Trias i Pujol ICO

    Badalona, 08916

    Enric Carcereny, Site 0123, 34934978925

    Recruiting

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, 08025

    Margarita Majem Tarruella, Site 0384, 34935565651

    Recruiting

  • Hospital Universitari Vall d Hebron

    Barcelona, 08035

    Eva Munoz, Site 0091, +34932746085

    Recruiting

  • Hospital Clinic de Barcelona

    Barcelona, 08036

    Maria Reig, Site 0323, 34932279803

    Recruiting

  • Local Institution - 0026

    Barcelona, 08036

    Completed

  • Local Institution - 0225

    Barcelona, 08908

    Completed

  • Local Institution

    Barcelona, 8025

    Withdrawn

  • Local Institution - 0146

    Burgos, 09006

    Completed

  • Local Institution - 0047

    Donostia / San Sebastian, Guipuzcoa, 20014

    Completed

  • Local Institution - 0144

    Granada, 18014

    Withdrawn

  • Local Institution - 0273

    Madrid, 28007

    Withdrawn

  • Local Institution - 0357

    Madrid, 28009

    Withdrawn

  • Clinica Universidad de Navarra Madrid

    Madrid, 28027

    Ignacio Melero Bermejo, Site 0360, 34948255400

    Recruiting

  • Local Institution - 0008

    Madrid, 28033

    Completed

  • Local Institution

    Madrid, 28033

    Withdrawn

  • Local Institution - 0027

    Madrid, 28034

    Completed

  • Hospital Universitario Fundacion Jimenez Diaz

    Madrid, 28040

    Manuel Domine Gomez, Site 0112, 34915504800

    Recruiting

  • Hospital Universitario 12 de Octubre

    Madrid, 28041

    Luis Paz-Ares Rodriguez, Site 0116, 3491434914692313

    Recruiting

  • Local Institution - 0380

    Madrid, 28046

    Completed

  • Local Institution

    Madrid, 28046

    Withdrawn

  • Hospital Universitario HM Sanchinarro

    Madrid, 28050

    Juan Rodriguez Moreno, Site 0097, 34917567984

    Recruiting

  • Local Institution - 0287

    Majadahonda, Madrid, 28220

    Completed

  • Local Institution - 0192

    Málaga, 29010

    Completed

  • Clinica Universidad de Navarra

    Pamplona, Navarre, 31008

    Ignacio Melero Bermejo, Site 0353, 34948255400

    Recruiting

  • Local Institution

    Santa Cruz de Tenerife, 38230

    Withdrawn

  • Hospital Universitario Marques de Valdecilla

    Santander, 39008

    Ignacio Jose Duran Martinez, Site 0352, 34942202515

    Recruiting

  • Local Institution - 0274

    Seville, 41009

    Completed

  • Local Institution - 0294

    Seville, 41013

    Completed

  • Hospital General Universitario de Valencia

    Valencia, 46014

    Alfonso Berrocal, Site 0020

    Recruiting

  • Local Institution - 0117

    Valencia, 46026

    Completed

Other trials in Spain

Germany31 sites, 7 recruiting

  • Universitaetsklinikum Aachen

    Aachen, 52074

    Matthias Saar, Site 0163, 0049241800

    Recruiting

  • Local Institution - 0248

    Berlin, 10117

    Completed

  • Local Institution - 0249

    Buxtehude, 21614

    Completed

  • Local Institution - 0296

    Cologne, 50937

    Withdrawn

  • Local Institution

    Cologne, 50937

    Withdrawn

  • Evangelische Kliniken Essen Mitte. Evang. Huyssens-Stiftung Essen-Huttrop

    Essen, North Rhine-Westphalia, 45136

    Sebastian Ertl, Site 0402, 4920117424001

    Recruiting

  • Local Institution - 0250

    Essen, North Rhine-Westphalia, 45147

    Completed

  • Local Institution - 0375

    Essen, North Rhine-Westphalia, 45147

    Withdrawn

  • University of Freiburg

    Freiburg im Breisgau, 79106

    Roland Roelz, Site 0315, 004976127050230

    Recruiting

  • Local Institution

    Gera, 07548

    Withdrawn

  • SRH Wald-Klinikum Gera GmbH

    Gera, 07548

    Sabine Sell, Site 0080, 493658287758

    Recruiting

  • Local Institution - 0076

    Göttingen, 37075

    Completed

  • Local Institution

    Göttingen, 37075

    Withdrawn

  • Local Institution - 0241

    Hamburg, 20246

    Completed

  • Local Institution

    Heidelberg, 69120

    Withdrawn

  • Thoraxklinik

    Heidelberg, 69126

    Helge Bischoff, Site 0148, 4962213961304

    Recruiting

  • Local Institution - 0342

    Heidelberg, D-69120

    Completed

  • SLK-Kliniken Heilbronn GmbH

    Heilbronn, 74078

    Uwe Martens, Site 0285, 4971314928700

    Recruiting

  • Universitaetsklinikum Jena - Klinik und Poliklinik fuer Urologie

    Jena, 07747

    Marc-Oliver Grimm, Site 0216, +49(0)36419329901

    Recruiting

  • Local Institution - 0288

    Kassel, 34125

    Completed

  • Local Institution - 0072

    Kiel, 24105

    Completed

  • Local Institution

    Kiel, 24105

    Withdrawn

  • Local Institution - 0386

    Löwenstein, Baden-Wurttemberg, 74245

    Withdrawn

  • Local Institution - 0298

    Löwenstein, 74245

    Withdrawn

  • Local Institution - 0098

    Lübeck, 23538

    Withdrawn

  • Local Institution - 0089

    Mainz, 55131

    Completed

  • Local Institution

    Mainz, 55131

    Withdrawn

  • Local Institution - 0276

    Munich, Bavaria, 80337

    Completed

  • Local Institution - 0332

    Nuremberg, Bavaria, 90419

    Withdrawn

  • Local Institution - 0017

    Tübingen, 72076

    Completed

  • Local Institution - 0277

    Tübingen, 72076

    Withdrawn

Other trials in Germany

Italy27 sites, 5 recruiting

  • Local Institution - 0034

    Bari, 70124

    Completed

  • Local Institution - 0002

    Bergamo, 24127

    Completed

  • Local Institution - 0326

    Candiolo, 10060

    Withdrawn

  • Local Institution - 0359

    Catania, 95123

    Completed

  • Local Institution - 0251

    Genova, 16132

    Completed

  • Local Institution

    Genova, 16132

    Withdrawn

  • IRCCS - Istituto Scientifico Romagnolo per lo Studio dei Tumori - Dino Amadori - Srl

    Meldola, Fc, 47014

    Angelo Delmonte, Site 0361, +393487469100

    Recruiting

  • Local Institution - 0108

    Meldola, 47014

    Withdrawn

  • Local Institution - 0303

    Meldola, 47014

    Withdrawn

  • Fondazione IRCCS istituto Neurologico Carlo Besta;

    Milan, 20133

    Elena Anghileri, Site 0312, 00390223942285

    Recruiting

  • Local Institution - 0096

    Milan, 20133

    Completed

  • Local Institution - 0351

    Milan, 20133

    Withdrawn

  • Local Institution

    Milan, 20133

    Withdrawn

  • Local Institution - 0071

    Milan, 20141

    Completed

  • Local Institution - 0267

    Milan, 20141

    Completed

  • Local Institution

    Milan, 20141

    Withdrawn

  • Local Institution - 0327

    Modena, 41124

    Withdrawn

  • Local Institution - 0073

    Naples, 80131

    Completed

  • Local Institution - 0218

    Naples, 80131

    Completed

  • Local Institution - 0292

    Naples, 80138

    Withdrawn

  • Istituto Oncologico Veneto

    Padova, 35128

    Umberto Basso, Site 0067, +39-049-8215953

    Recruiting

  • Local Institution - 0180

    Ravenna, 48121

    Completed

  • Istituto Nazionale dei Tumori Regina Elena

    Roma, RM, 00144

    Michelangelo Russillo, Site 0033, 0652662745

    Recruiting

  • Local Institution - 0333

    Rozzano, MI, 20089

    Withdrawn

  • Local Institution - 0003

    Siena, 53100

    Completed

  • Local Institution - 0291

    Terni, 05100

    Withdrawn

  • Azienda Ospedaliera Citta della Salute e della Scienza

    Torino, 10126

    Alessia Pellerino, Site 0313, +390116334904

    Recruiting

Other trials in Italy

France25 sites, 9 recruiting

  • Local Institution - 0006

    Bordeaux, Gironde, 33075

    Completed

  • Centre Jean Perrin

    Clermont-Ferrand, 63011

    Hakim Mahammedi, Site 0345, 33473278131

    Recruiting

  • Local Institution - 0107

    Créteil, 94010

    Completed

  • Local Institution - 0074

    Dijon, 21000

    Completed

  • Local Institution - 0109

    Dijon, 21079

    Completed

  • CHU Grenobles Alpes

    La Tronche, 38700

    Julie Charles, Site 0010, +33476766493

    Recruiting

  • Pole Biologie Pathologie Genetique - CHU de Lille

    Lille, 59037

    Laurent Mortier, Site 0011

    Recruiting

  • APHM - Hopital de la Timone

    Marseille, 13385

    Caroline Gaudy, Site 0125, 33491387991

    Recruiting

  • Local Institution - 0153

    Marseille, 13915

    Completed

  • CHU Montpellier

    Montpellier, 34090

    Lea Fornero, Site 0182, 0665849187

    Recruiting

  • Local Institution

    Montpellier, 34295

    Withdrawn

  • Local Institution - 0300

    Nantes, 44093

    Withdrawn

  • Local Institution - 0341

    Nantes, 44093

    Completed

  • Local Institution - 0028

    Paris, 75010

    Completed

  • Local Institution - 0301

    Paris, 75018

    Withdrawn

  • Local Institution - 0167

    Paris, 75908

    Completed

  • Local Institution - 0387

    Paris, Île-de-France Region, 75005

    Withdrawn

  • Centre Hospitalier Lyon Sud

    Pierre-Bénite, 69495

    Stephane Dalle, Site 0084, 3333478861679

    Recruiting

  • Local Institution

    Rennes, 35033

    Withdrawn

  • CHU de Saint-Etienne - Hopital Nord

    Saint-Priest-en-Jarez, 42270

    Pierre CORNILLON, Site 0401, +477917000

    Recruiting

  • Hopital Foch

    Suresnes, 92151

    CHRISTINE ABRAHAM, Site 0392, +33676018749

    Recruiting

  • Local Institution - 0156

    Toulon, 83 056

    Completed

  • Local Institution

    Toulouse, 31059

    Withdrawn

  • Local Institution - 0362

    Vandœuvre-lès-Nancy, Meurthe-Et-Moselle, 54500

    Completed

  • Institut Gustave Roussy

    Villejuif, 94805

    Caroline Robert, Site 0029, 33142114210

    Recruiting

Other trials in France

China23 sites, 11 recruiting

  • Local Institution - 0198

    Beijing, Beijing Municipality, 100853

    Withdrawn

  • Jilin University (JLU) - First Affiliated Hospital - Cancer Center

    Changchun, Jilin, 130061

    Wei Li, Site 0307, 8613756661267

    Recruiting

  • Jilin Cancer Hospital

    Changchun, Jilin, 130103

    Ying Liu, Site 0194

    Recruiting

  • Local Institution - 0172

    Changsha, Hunan, 410000

    Withdrawn

  • Xiangya Hospital Central South University

    Changsha, Hunan, 410008

    Min Li, Site 0309, 8613787103054

    Recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, 410011

    Shanzhi Gu, Site 0316, +73188651669

    Recruiting

  • Local Institution

    Guangzhou, Guangdong, 510080

    Withdrawn

  • Nanfang Hospital; Southern Medical University

    Guangzhou, Guangdong, 510515

    Ya-Bing Guo, Site 0383, 862061641945

    Recruiting

  • Sir Run Run Shaw Hospital

    Hangzhou, Zhejiang, 310016

    Enguo Chen, Site 0304, 13588706779

    Recruiting

  • Local Institution - 0306

    Hangzhou, 310003

    Completed

  • Local Institution - 0245

    Harbin, Heilongjiang, 150040

    Withdrawn

  • Harbin Medical University - Cancer Hospital

    Harbin, Heilongjiang, 150081

    Yuxian Bai, Site 0317, 8613945095085

    Recruiting

  • Local Institution - 0160

    Harbin, Heilongjiang, 150081

    Completed

  • Local Institution - 0169

    Hefei, Anhui, 230031

    Withdrawn

  • Local Institution - 0348

    Nanjing, Jiangsu, 210009

    Withdrawn

  • Jiangsu Cancer Hospital

    Nanjing, 210009

    Qing Zou, Site 0390, 13905173337

    Recruiting

  • Local Institution - 0223

    Shanghai, Shanghai Municipality, 200025

    Completed

  • Fudan University - Shanghai Cancer Center FUSCC

    Shanghai, Shanghai Municipality, 200032

    Xianghua Wu, Site 0305, 8613482888167

    Recruiting

  • Local Institution - 0278

    Shanghai, Shanghai Municipality, 200032

    Withdrawn

  • Local Institution - 0325

    Shanghai, Shanghai Municipality, 200032

    Withdrawn

  • Local Institution - 0188

    Shanghai, Shanghai Municipality, 200433

    Completed

  • Tangdu Hospital of Fourth Military Medical University

    Xi'an, Shaanxi, 710038

    Haichuan Su, Site 0318

    Recruiting

  • Xian International Medical Center Hospital

    Xi'an, Shan3XI, 710700

    Guohong Han, Site 0395, 86+8613991969930

    Recruiting

Other trials in China

Japan23 sites, 10 recruiting

  • Tokyo Women's Medical University - Adachi Medical Center

    Adachi-Ku, Tokyo, 1238558

    Tsunenori Kondo, Site 0406

    Recruiting

  • Institute of Science Tokyo Hospital

    Bunkyo-Ku, Tokyo, 1138519

    Shohei Fukuda, Site 0404, 81358035295

    Recruiting

  • Chiba Cancer Center

    Chiba, Chiba, 2608717

    Atsushi Komaru, Site 0409, 81432645431

    Recruiting

  • Local Institution - 0235

    Chuo-ku, Tokyo, 1040045

    Completed

  • Kyushu University Hospital

    Fukuoka, Fukuoka, 812-8582

    Takashi Matsumoto, Site 0393, 81926425603

    Recruiting

  • Local Institution - 0224

    Fukuoka, 11111

    Withdrawn

  • Hamamatsu University Hospital

    Hamamatsu, Shizuoka, 431-3192

    Teruo Inamoto, Site 0391, 0534362306

    Recruiting

  • Local Institution - 0242

    Hirosaki-shi, Aomori, 036-8563

    Completed

  • Hiroshima University Hospital

    Hiroshima, 7348551

    Tomokazu Kawaoka, Site 0319, 81822575555

    Recruiting

  • Local Institution - 0219

    Kanazawa, Ishikawa-ken, 920-8641

    Withdrawn

  • National Cancer Center Hospital East

    Kashiwa-Shi, Chiba, 2778577

    Toshihiko Doi, Site 0356, 81335422511

    Recruiting

  • Local Institution - 0211

    Kobe, Hyōgo, 6500047

    Completed

  • Local Institution - 0217

    Koto-Ku, Tokyo, 135-8550

    Completed

  • Ehime Prefectural Central Hospital

    Matsuyama, Ehime, 7900024

    Fujimasa Tada, Site 0394

    Recruiting

  • National Hospital Organization Shikoku Cancer Center

    Matsuyama, Ehime, 7910280

    Katsuyoshi Hashine, Site 0397, 81899991111

    Recruiting

  • Local Institution - 0222

    Natori-shi, Miyagi, 981-1293

    Completed

  • Local Institution - 0230

    Niigata, Niigata, 9518566

    Completed

  • Local Institution - 0236

    Niigata, 951-8520

    Completed

  • Local Institution - 0214

    Sayama, Osaka, 5898511

    Completed

  • Local Institution - 0239

    Shinjuku, Tokyo, 160-8582

    Completed

  • Local Institution - 0212

    Takatsuki, Osaka, 569-8686

    Completed

  • Local Institution - 0240

    Tsukuba, Ibaraki, 305-8576

    Completed

  • Yokohama City University Medical Center

    Yokohama, Kanagawa, 2320024

    Manabu Morimoto, Site 0368, 81452615656

    Recruiting

Other trials in Japan

Australia15 sites, 5 recruiting

  • Local Institution

    Adelaide, South Australia, 5000

    Withdrawn

  • BRICC - Ballarat Health Services

    Ballarat, Victoria, 3350

    Wasek Faisal, Site 0411

    Recruiting

  • Local Institution - 0045

    Coffs Harbour, New South Wales, 2450

    Completed

  • Local Institution - 0196

    Elizabeth Vale, South Australia, 05112

    Completed

  • Local Institution - 0365

    Fitzroy, Victoria, 3065

    Completed

  • Gallipoli Medical Foundation

    Greenslopes, Queensland, 4120

    Victoria Atkinson, Site 0021, 0448632604

    Recruiting

  • Local Institution - 0372

    Greenslopes, Queensland, 4120

    Withdrawn

  • Cabrini Hospital Malvern

    Malvern, Victoria, 3144

    Benjamin Brady, Site 0005, 0395086161

    Recruiting

  • Local Institution - 0174

    Murdoch, Western Australia, 6150

    Withdrawn

  • Melanoma Institute Australia

    North Sydney, New South Wales, 2060

    Georgina Long, Site 0062, 61299117336

    Recruiting

  • Local Institution

    South Brisbane, Queensland, 4101

    Withdrawn

  • Tasman Oncology Research Ltd

    Southport, Queensland, 4215

    Andrew Hill, Site 0347, +61756132480

    Recruiting

  • Local Institution - 0009

    Sydney, New South Wales, 2050

    Completed

  • Local Institution - 0193

    Waratah, New South Wales, 2298

    Completed

  • Local Institution - 0208

    Westmead, New South Wales, 2145

    Completed

Other trials in Australia

Brazil15 sites, 5 recruiting

  • Local Institution - 0264

    Barretos, São Paulo, 14784-400

    Completed

  • Local Institution - 0260

    Belo Horizonte, Minas Gerais, 30130090

    Completed

  • ONCOSITE - Centro de Pesquisa Clinica em Oncologia

    Ijuí, Rio Grande do Sul, 98700-000

    Fabio Franke, Site 0155, +5555991592101

    Recruiting

  • Local Institution - 0379

    Passo Fundo, Rio Grande do Sul, 99010-080

    Withdrawn

  • Local Institution - 0093

    Porto Alegre, Rio Grande do Sul, 90035-903

    Site 0093

    Not yet recruiting

  • Irmandade da Santa Casa de Misericordia de Porto Alegre

    Porto Alegre, Rio Grande do Sul, 90050-170

    Rodrigo Pereira, Site 0113, 555133598619

    Recruiting

  • Hospital Sao Lucas Da Pucrs

    Porto Alegre, Rio Grande do Sul, 90610-000

    Carlos Barrios, Site 0331, +555133203039

    Recruiting

  • Local Institution - 0399

    Porto Alegre, Rio Grande do Sul, 91350-250

    Withdrawn

  • Local Institution - 0266

    Rio de Janeiro, 20220-280

    Completed

  • Local Institution - 0258

    Rio de Janeiro, 22775-001

    Completed

  • Local Institution - 0262

    São José do Rio Preto, São Paulo, 15090-000

    Completed

  • ICESP - Instituto do Cancer do Estado de Soo Paulo

    São Paulo, São Paulo, 01246-000

    Olavo Feher, Site 0302, 551138932684

    Recruiting

  • Local Institution - 0263

    São Paulo, São Paulo, 01308-050

    Withdrawn

  • Local Institution - 0355

    São Paulo, São Paulo, 01327-001

    Completed

  • Local Institution - 0340

    São Paulo, 01308-060

    Withdrawn

Other trials in Brazil

Poland15 sites, 6 recruiting

  • Local Institution - 0336

    Biała Podlaska, 21-500

    Withdrawn

  • Centrum Onkologii im. Prof. Franciszka Lukaszczyka

    Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 85-796

    Bogdan Zurawski, Site 0358, +48501446778

    Recruiting

  • Local Institution - 0120

    Gdansk, 80-214

    Completed

  • Wojewodzkie Centrum Onkologii

    Gdansk, 80219

    Joanna Wojcik-Tomaszewska, Site 0069, 4858505993747

    Recruiting

  • Local Institution - 0377

    Krakow, 30-510

    Withdrawn

  • Local Institution - 0252

    Krakow, 31-115

    Completed

  • Local Institution - 0373

    Krakow, 31-501

    Withdrawn

  • Instytut MSF Sp zoo

    Lodz, 90-302

    Ewa Kalinka, Site 0031

    Recruiting

  • Local Institution - 0118

    Lublin, 20-064

    Completed

  • Warminsko-Mazurskie Centrum Chorob Pluc w Olsztynie

    Olsztyn, Warmian-Masurian Voivodeship, 10-357

    Andrzej Kazarnowicz, Site 0414, 48895322973

    Recruiting

  • Local Institution - 0178

    Poznan, 60-185

    Completed

  • Wojskowy Instytut Medyczny

    Warsaw, 0 4-141

    Renata Duchnowska, Site 0132, +48602609988

    Recruiting

  • Local Institution - 0328

    Warsaw, 02-776

    Withdrawn

  • Local Institution

    Warsaw, 02-781

    Withdrawn

  • Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology

    Warsaw, 02-781

    Dariusz Kowalski, Site 0151, 48225463066

    Recruiting

Other trials in Poland

Mexico14 sites, 6 recruiting

  • Cryptex Investigacion Clinica Sa de Cv

    Cuauhtémoc, Mexico City, 06100

    Daniel Motola Kuba, Site 0337, 5215585815263

    Recruiting

  • Local Institution - 0152

    León, Guanajuato, 37000

    Withdrawn

  • Local Institution - 0346

    México, 14080

    Completed

  • Local Institution - 0410

    Mexico City, 03810

    Withdrawn

  • Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

    Mexico City, 14080

    Maria Bourlon, Site 0344, 5215554386271

    Recruiting

  • Local Institution - 0286

    Monterrey, Nuevo León, 64040

    Withdrawn

  • Local Institution - 0354

    Monterrey, Nuevo León, 64460

    Withdrawn

  • I Can Oncology Center

    Monterrey, Nuevo León, 64710

    Yamil Alonso Lopez Chuken, Site 0396

    Recruiting

  • Local Institution - 0007

    Morelia, Michoacán, 58240

    Completed

  • Centro de Investigacion Clinica de Oaxaca

    Oaxaca City, Oaxaca, CP68020

    Roberto Romero Diaz, Site 0369, +529512570569

    Recruiting

  • Local Institution - 0343

    Querétaro City, Querétaro, 76000

    Withdrawn

  • Centro Potosino de Investigacion Medica S.C.

    San Luis Potosí City, 78250

    Pedro Figueroa Martinez, Site 0367, 4444479873

    Recruiting

  • Local Institution - 0181

    Tlalpan, Mexico City, 14050

    Withdrawn

  • Investigación Biomédica para el Desarrollo de Fármacos S.A de C.V

    Zapopan, Jalisco, 45070

    EMILIO MURILLO, Site 0338, +523311938595

    Recruiting

Other trials in Mexico

Argentina11 sites, 6 recruiting

  • Local Institution - 0199

    Berazategui, Buenos Aires, 1880

    Completed

  • Local Institution - 0201

    Buenos Aires, C1199 ABH

    Withdrawn

  • Instituto Fleming

    Buenos Aires, C1426ANZ

    Matias Chacon, Site 0030, +541138850425

    Recruiting

  • Local Institution

    CABA, C1426ANZ

    Withdrawn

  • Fundacion Richardet Longo - IONC

    Córdoba, X 5002HWE

    Martin Richardet, Site 0349, 5493516165267

    Recruiting

  • Local Institution - 0170

    Córdoba, X5004FHP

    Withdrawn

  • Instituto Medico Rio Cuarto

    Río Cuarto, Córdoba Province, 5800

    Alejo Lingua, Site 0415, 54351153819050

    Recruiting

  • Sanatorio Parque

    Rosario, Santa Fe Province, 2000

    Gaston Lucas Martinengo, Site 0407

    Recruiting

  • CAIPO Centro para la Atencion Integral del Paciente Oncologico

    San Miguel de Tucumán, Tucumán Province, 4000

    Felipe Salvador Palazzo, Site 0376, 543814018300

    Recruiting

  • Local Institution - 0191

    San Miguel de Tucumán, Tucumán Province, 4000

    Completed

  • Centro de Investigaciones Clinicas. Clinica Viedma S.A.

    Viedma, Río Negro Province, 8500

    Ruben Kowalyszyn, Site 0405, 5492920601693

    Recruiting

Other trials in Argentina

United Kingdom10 sites, 1 recruiting

  • Local Institution - 0299

    Edinburgh, Scotland, EH4 2XU

    Withdrawn

  • Local Institution - 0259

    Glasgow, G12 0YN

    Withdrawn

  • Local Institution - 0141

    London, Greater London, N18 1QX

    Completed

  • University College Hospital

    London, Greater London, NW1 2PG

    Paul Mulholland, Site 0314, +44 20 3456 7890

    Recruiting

  • Local Institution - 0272

    London, Greater London, SM2 5PT

    Completed

  • Local Institution - 0086

    London, Greater London, SW3 6JJ

    Completed

  • Local Institution - 0231

    Maidstone, Kent, ME16 9QQ

    Withdrawn

  • Local Institution - 0115

    Manchester, Greater Manchester, M20 4BX

    Completed

  • Local Institution - 0161

    Northwood, Middlesex, HA6 2RN

    Completed

  • Local Institution - 0195

    Southampton, Hampshire, SO16 6YD

    Completed

Other trials in United Kingdom

Greece9 sites, 1 recruiting

  • Alexandra Hospital

    Athens, Attica, 11528

    Michail Liontos, Site 0381, 3021232162845

    Recruiting

  • Local Institution - 0022

    Athens, 11527

    Completed

  • Local Institution - 0126

    Athens, 11527

    Completed

  • Local Institution - 0171

    Athens, 11528

    Completed

  • Local Institution - 0042

    Athens, 18547

    Completed

  • Local Institution - 0295

    Athens, 18547

    Withdrawn

  • Local Institution - 0244

    Heraklion, Crete, 710 03

    Withdrawn

  • Local Institution

    Pátrai, 26504

    Withdrawn

  • Local Institution - 0215

    Thessaloniki, 57001

    Completed

Other trials in Greece

Romania9 sites, 5 recruiting

  • Local Institution - 0310

    Bucharest, Sector 2, 021389

    Completed

  • Institutul Oncologic Bucuresti IOB

    Bucharest, 022328

    Aurelia Alexandru, Site 0129, 40723289606

    Recruiting

  • Institutul Oncologic Prof. Dr. I. Chiricuta

    Cluj-Napoca, Cluj, 400015

    Tudor Ciuleanu, Site 0135, 40745646368

    Recruiting

  • Local Institution - 0127

    Cluj-Napoca, 400-641

    Completed

  • Local Institution - 0189

    Cluj-Napoca, 400015

    Completed

  • Onco Clinic Consult SA

    Craiova, Dolj, 200508

    Patricia Visan, Site 0378, +40724280084

    Recruiting

  • Centrul de Oncologie Sf Nectarie

    Craiova, Dolj, 200542

    Michael Schenker, Site 0265, 40727774974

    Recruiting

  • Local Institution - 0133

    Oradea, 410469

    Completed

  • Sc Sigmedical Srl

    Suceava, 720214

    Doina Ganea, Site 0374, +40722423653

    Recruiting

Other trials in Romania

Canada7 sites, 2 recruiting

  • Cross Cancer Institute

    Edmonton, Alberta, T6G 1Z2

    Quincy Chu, Site 0111, 7804328248

    Recruiting

  • Local Institution

    Halifax, Nova Scotia, B3H1V7

    Withdrawn

  • Local Institution - 0040

    Montreal, Quebec, H4A 3J1

    Withdrawn

  • Local Institution - 0308

    Montreal, Quebec, H4J 1C5

    Withdrawn

  • Local Institution - 0168

    Oshawa, Ontario, L1G 2B9

    Completed

  • Princess Margaret Cancer Centre

    Toronto, Ontario, M5G 2M9

    Marcus Butler, Site 0280, 4169464628

    Recruiting

  • Local Institution

    Vancouver, British Columbia, V5Z 1L3

    Withdrawn

Other trials in Canada

South Korea7 sites, 2 recruiting

  • National Cancer Center

    Gyeonggi-do, 10408

    BoHyun Kim, Site 0320

    Recruiting

  • Local Institution - 0389

    Seongnam-si, Gyeonggi-do, 13532

    Withdrawn

  • Local Institution - 0221

    Seongnam-si, 463-707

    Completed

  • Asan Medical Center

    Seoul, Songpa-gu, 05505

    Min-Hee Ryu, Site 0322, 82230105935

    Recruiting

  • Local Institution - 0206

    Seoul, 03722

    Completed

  • Local Institution - 0324

    Seoul, 110 - 744

    Completed

  • Local Institution - 0207

    Suwon, 16499

    Completed

Other trials in South Korea

Belgium6 sites

  • Local Institution - 0329

    Brussels, 1000

    Withdrawn

  • Local Institution - 0232

    Ghent, 9000

    Completed

  • Local Institution - 0139

    Jette, 1090

    Completed

  • Local Institution - 0261

    Liège, 4000

    Withdrawn

  • Local Institution - 0293

    Sint-Niklaas, 9100

    Withdrawn

  • Local Institution - 0157

    Yvoir, 5530

    Completed

Other trials in Belgium

Chile6 sites, 3 recruiting

  • Orlandi Oncologia

    Providencia, Santiago Metropolitan, 7500713

    Francisco Orlandi Jorquera, Site 0398, 5656224339699

    Recruiting

  • Bradford Hill Centro de Investigacion Clinica

    Santiago, Santiago Metropolitan, 0

    Mauricio Burotto, Site 0101

    Recruiting

  • Fundacion Arturo Lopez Perez

    Santiago, Santiago Metropolitan, 7500921

    Mauricio Mahave, Site 0019, 5624205100

    Recruiting

  • Local Institution

    Santiago, Santiago Metropolitan, 7500921

    Withdrawn

  • Local Institution - 0363

    Temuco, Araucania, 4780000

    Completed

  • Local Institution - 0079

    Viña del Mar, 2540364

    Withdrawn

Other trials in Chile

Austria5 sites, 1 recruiting

  • Local Institution - 0254

    Graz, Styria, 8036

    Completed

  • Ordensklinikum Linz GmbH Elisabethinen

    Linz, Upper Austria, 4020

    Clemens Mayr, Site 0149, 4373276764600

    Recruiting

  • Local Institution - 0104

    Vienna, 1090

    Completed

  • Local Institution - 0321

    Vienna, 1090

    Completed

  • Local Institution - 0145

    Wels, 4600

    Completed

Other trials in Austria

Czechia5 sites, 1 recruiting

  • Local Institution - 0371

    Brno, 656 53

    Withdrawn

  • FNHK Klinika onkologie a radioterapie

    Hradec Králové, 500 05

    Jindrich Kopecky, Site 0243, +420495832176

    Recruiting

  • Local Institution - 0150

    Olomouc, 779 00

    Withdrawn

  • Local Institution - 0253

    Prague, 11000

    Withdrawn

  • Local Institution - 0275

    Prague, 128 00

    Completed

Other trials in Czechia

Israel5 sites

  • Local Institution - 0190

    Haifa, 3109601

    Completed

  • Local Institution - 0270

    Jerusalem, 91120

    Completed

  • Local Institution

    Petah Tikva, 49100

    Withdrawn

  • Local Institution - 0052

    Ramat Gan, 52621

    Completed

  • Local Institution - 0350

    Tiqwa, 49100

    Withdrawn

Other trials in Israel

Hungary4 sites

  • Local Institution - 0159

    Budapest, 1121

    Completed

  • Local Institution - 0226

    Budapest, 1121

    Withdrawn

  • Local Institution - 0187

    Debrecen, 4032

    Completed

  • Local Institution - 0290

    Gyöngyössolymos, Heves County, 3233

    Completed

Other trials in Hungary

New Zealand4 sites, 1 recruiting

  • Auckland City Hospital

    Auckland, 1142

    Edward Gane, Site 0370, 6921548371

    Recruiting

  • Local Institution - 0271

    Christchurch, 8011

    Withdrawn

  • Local Institution - 0268

    Dunedin, 9016

    Completed

  • Local Institution - 0269

    Tauranga, 3112

    Completed

Other trials in New Zealand

Russia4 sites

  • Local Institution - 0257

    Krasnodar, Krasnodarskiy Kray, 350040

    Withdrawn

  • Local Institution - 0256

    Krasnoyarsk, 660133

    Withdrawn

  • N.N. Blokhin National Medical Research Center of Oncology

    Moscow, 115478

    Terminated

  • VitaMed LLC

    Moscow, 121309

    Terminated

Other trials in Russia

Taiwan4 sites, 2 recruiting

  • Taichung Veterans General Hospital

    Taichung, 40705

    Teng-Yu Lee, Site 0388, 8864235925253309

    Recruiting

  • Local Institution - 0197

    Tainan, 704

    Completed

  • Local Institution - 0412

    Taipei, 10002

    Completed

  • Taipei Veterans General Hospital TPVGH

    Taipei, 11217

    Yi-Hsiang Huang, Site 0366, +886938590872

    Recruiting

Other trials in Taiwan

Portugal3 sites

  • Local Institution - 0184

    Lisbon, 1769-001

    Completed

  • Local Institution - 0177

    Lisbon, 4200-072

    Completed

  • Local Institution - 0142

    Porto, 4200319

    Withdrawn

Other trials in Portugal

Sweden3 sites

  • Local Institution

    Gothenburg, SE-41345

    Withdrawn

  • Local Institution - 0036

    Malmö, 205 02

    Withdrawn

  • Local Institution

    Umeå, 901 85

    Withdrawn

Other trials in Sweden

Switzerland3 sites

  • Local Institution - 0119

    Basel, 4031

    Completed

  • Local Institution - 0403

    Sankt Gallen, 9007

    Withdrawn

  • Local Institution - 0083

    Zurich, CH - 8058

    Completed

Other trials in Switzerland

Ireland2 sites

  • Local Institution - 0227

    Dublin, Dublin 7

    Withdrawn

  • Local Institution

    Limerick, V94 F858

    Withdrawn

Other trials in Ireland

Netherlands2 sites

  • Local Institution - 0335

    Amsterdam, North Holland, 1066 CX

    Withdrawn

  • Local Institution

    Rotterdam, 3015 CE

    Withdrawn

Other trials in Netherlands

Norway2 sites

  • Local Institution - 0213

    Bergen, 5021

    Completed

  • Local Institution - 0048

    Oslo, N-0379

    Completed

Other trials in Norway

Peru2 sites, 1 recruiting

  • Local Institution - 0385

    Lima, 15076

    Site 0385

    Not yet recruiting

  • Local Institution - 0179

    Santiago de Surco, Lima region, 15023

    Completed

Other trials in Peru

Puerto Rico2 sites, 2 recruiting

  • FDI Clinical Research

    San Juan, PR, 00927

    Mirelis Acosta-Rivera, Site 0334, 7877520003545

    Recruiting

  • Local Institution - 0416

    San Juan, 918

    Site 0416

    Not yet recruiting

Other trials in Puerto Rico

Denmark1 site

  • Local Institution

    Odense C, 5000

    Withdrawn

Other trials in Denmark

Finland1 site

  • Local Institution

    Helsinki, 00029

    Withdrawn

Other trials in Finland

Hong Kong1 site, 1 recruiting

  • Queen Mary Hospital

    Hong Kong, 000000

    Thomas Yau, Site 0339, 85222554249

    Recruiting

Other trials in Hong Kong

Turkey (Türkiye)1 site

  • Local Institution - 0330

    Ankara, 06010

    Withdrawn

Other trials in Turkey (Türkiye)

About this study

Official title: Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies

Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.

Conditions
Cancer
Being tested
Nivolumab, Ipilimumab, Cabozantinib, Trametinib, Relatlimab
Keywords
Rollover, pan-tumor
Medical subject headings
Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • NivolumabDrug

    Also called BMS-936558-01

    Specified dose on specified days

  • IpilimumabDrug

    Specified dose on specified days

  • CabozantinibDrug

    Specified dose on specified days

  • TrametinibDrug

    Specified dose on specified days

  • RelatlimabDrug

    Also called BMS-986016-01

    Specified dose on specified days

  • Nivolumab + RelatlimabDrug

    Also called BMS-986213

    Specified dose on specified days

  • CapecitabineDrug

    Specified dose on specified days

  • BevacizumabDrug

    Specified dose on specified days

  • TemozolomideDrug

    Specified dose on specified days

  • RucaparibDrug

    Specified dose on specified days

  • DaratumumabDrug

    Specified dose on specified days

  • RegorafinibDrug

    Specified dose on specified days

  • LeucovorinDrug

    Specified dose on specified days

  • FluorouracilDrug

    Specified dose on specified days

  • OxaliplatinDrug

    Specified dose on specified days

  • EnzalutamideDrug

    Specified dose on specified days

  • SunitinibDrug

    Specified dose on specified days

  • PemetrexedDrug

    Specified dose on specified days

  • PembrolizumabDrug

    Specified dose on specified days

Study groups in NCT03899155
Study groupRoleWhat they receive
A1: Nivolumab Monotherapy Dose 1ExperimentalNot described
Receives: Drug: Nivolumab
A2: Nivolumab Monotherapy Dose 2ExperimentalNot described
Receives: Drug: Nivolumab
B1: Nivolumab + IpilimumabExperimentalNot described
Receives: Drug: Nivolumab; Drug: Ipilimumab
B2: Nivolumab + Ipilimumab + CabozantinibExperimentalNot described
Receives: Drug: Nivolumab; Drug: Ipilimumab; Drug: Cabozantinib
B3: Nivolumab + Ipilimumab + TrametinibExperimentalNot described
Receives: Drug: Nivolumab; Drug: Ipilimumab; Drug: Trametinib
C1: Relatlimab + Nivolumab Fixed Dose Combination Dose 1ExperimentalNot described
Receives: Drug: Nivolumab + Relatlimab
C3: Relatlimab + Nivolumab Fixed Dose Combination Dose 2ExperimentalNot described
Receives: Drug: Nivolumab + Relatlimab
C2: Relatlimab + Nivolumab Single Agent Vial (SAV) Dose 1ExperimentalNot described
Receives: Drug: Nivolumab; Drug: Relatlimab
C4: Relatlimab + Nivolumab SAV Dose 2ExperimentalNot described
Receives: Drug: Nivolumab; Drug: Relatlimab
C5: Relatlimab + Nivolumab + IpilimumabExperimentalNot described
Receives: Drug: Nivolumab; Drug: Ipilimumab
C6: Relatlimab + Nivolumab + CapecitabineExperimentalNot described
Receives: Drug: Nivolumab + Relatlimab; Drug: Capecitabine
C7: Relatlimab + Nivolumab SAV Dose 3ExperimentalNot described
Receives: Drug: Nivolumab; Drug: Relatlimab
C10: Relatlimab + Nivolumab SAV Dose 4ExperimentalNot described
Receives: Drug: Nivolumab; Drug: Relatlimab
C12: Relatlimab + Nivolumab SAV Dose 5ExperimentalNot described
Receives: Drug: Nivolumab; Drug: Relatlimab
C8: Relatlimab + Nivolumab SAV + PDCT Dose 1ExperimentalNot described
Receives: Drug: Nivolumab; Drug: Relatlimab
C9: Relatlimab + Nivolumab SAV + BevacizumabExperimentalNot described
Receives: Drug: Nivolumab; Drug: Relatlimab; Drug: Bevacizumab
C11: Relatlimab + Nivolumab SAV + PDCT Dose 2ExperimentalNot described
Receives: Drug: Nivolumab; Drug: Relatlimab
D1: Nivolumab + TemozolomideExperimentalNot described
Receives: Drug: Nivolumab; Drug: Temozolomide
D2: Nivolumab + RucaparibExperimentalNot described
Receives: Drug: Nivolumab; Drug: Rucaparib
D3: Nivolumab + DaratumumabExperimentalNot described
Receives: Drug: Nivolumab; Drug: Daratumumab
D4: Nivolumab + BevacizumabExperimentalNot described
Receives: Drug: Nivolumab
E1: Bevacizumab MonotherapyExperimentalNot described
Receives: Drug: Bevacizumab
E2: Regorafinib MonotherapyExperimentalNot described
Receives: Drug: Regorafinib
E4: Leucovorin + Oxaliplatin + FluorouracilExperimentalNot described
Receives: Drug: Leucovorin; Drug: Fluorouracil; Drug: Oxaliplatin
E5: Enzalutamide MonotherapyExperimentalNot described
Receives: Drug: Enzalutamide
E6: Sunitinib MonotherapyExperimentalNot described
Receives: Drug: Sunitinib
E7: Rucaparib MonotherapyExperimentalNot described
Receives: Drug: Rucaparib
E8: Capecitabine MonotherapyExperimentalNot described
Receives: Drug: Capecitabine
E9: Cabozantinib MonotherapyExperimentalNot described
Receives: Drug: Cabozantinib
E10: Pemetrexed MonotherapyExperimentalNot described
Receives: Drug: Pemetrexed
E11: Pembrolizumab MonotherapyExperimentalNot described
Receives: Drug: Pembrolizumab
E3: Leucovorin + FluorouracilExperimentalNot described
Receives: Drug: Leucovorin

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Incidence of Adverse Events (AEs)

    Measured: From Day 1 up to 135 Days after discontinuation of treatment

  2. Incidence of drug related AEs

    Measured: From Day 1 up to 135 Days after discontinuation of treatment

  3. Incidence of AEs leading to Discontinuation

    Measured: From Day 1 up to 135 Days after discontinuation of treatment

  4. Incidence of Serious Adverse Events (SAEs)

    Measured: From signature of Informed Consent up to 135 Days after discontinuation of treatment

  5. Incidence of Select AEs

    Measured: From Day 1 up to 135 Days after discontinuation of treatment

  6. Incidence of Immune-Mediated AEs

    Measured: From Day 1 up to 135 Days after discontinuation of treatment

  7. Incidence of Death

    Measured: From signature of Informed Consent up to 135 Days after discontinuation of treatment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Apr 2019
  2. Study start9 Aug 2019
  3. Primary completion25 Aug 2029 (estimated)
  4. Study completion25 Aug 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
1,500 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03899155
Sponsor's protocol ID
CA209-8TT
Other IDs
2018-004362-34, 2018
Status last verified
Sep 2026
First submitted
1 Apr 2019
Last updated
23 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Nivolumab, Ipilimumab and Cabozantinib in people with Cancer, run by Bristol-Myers Squibb at 399 sites in 38 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 23 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 399 sites in United States, Spain, Germany, Italy, France and 33 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact BMS Clinical Trials Contact Center www.BMSClinicalTrials.com (855-907-3286, Clinical.Trials@bms.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Incidence of Adverse Events (AEs) (time frame: From Day 1 up to 135 Days after discontinuation of treatment). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03899155.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Sep 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in